Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
ProQR Therapeutics N.V. (PRQR) PT Lowered to $2.50 at Chardan Capital Markets
-
ProQR Therapeutics N.V. (PRQR) PT Lowered to $18 at Chardan Capital Markets
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
ProQR (PRQR) Prices 9.09M Share Offering at $5.50/Sh
-
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
-
ProQR to Present at Two Investor Conferences in October
-
ProQR to Present at the Chardan Genetic Medicines Conference
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
ProQR (PRQR) Prices 5.75M Share Common Offering at $15.75/Sh
-
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
-
ProQR Therapeutics N.V. (PRQR) PT Raised to $21 at Chardan Capital Markets
-
Chardan Capital Markets Starts ProQR Therapeutics N.V. (PRQR) at Buy
-
ProQR to Present at the Chardan Inaugural Gene Therapy Conference
-
Notable Analyst Rating Changes 6/20: (YELP) (SAVE) (SYMC) Upgraded; (EGRX) (SCTY) (ESRX) Downgraded
-
UPDATE: Chardan Capital Markets Starts ProQR Therapeutics N.V. (PRQR) at Neutral

